Exclusive: Novo Nordisk cuts US obesity education team as layoffs begin, say sources, online posts

Novo Nordisk has eliminated its U.S. cardiometabolic educator sales team, comprising several hundred staff, as an initial step in a broader restructuring plan to cut costs and enhance competitiveness against Eli Lilly. This move, following a significant loss in market capitalization and the announcement of 9,000 global job cuts, signals CEO Maziar Mike Doustdar's strategy to streamline operations and regain market dominance in the weight-loss drug sector.

Analysis

Novo Nordisk is executing the initial phase of a significant corporate restructuring by eliminating its U.S. cardiometabolic educator team, a unit comprising several hundred employees. This action represents the first specific cut under new CEO Maziar Mike Doustdar's plan to reduce the global workforce by 9,000. The move is a direct response to intense competitive pressure from Eli Lilly, which has captured market dominance in the U.S. weight-loss drug sector and contributed to Novo Nordisk losing over $400 billion in market capitalization since the middle of last year. By disbanding a team focused on 'disease state education'—a function its primary rival Eli Lilly does not have—Novo is signaling a strategic shift to streamline operations and align its cost structure more closely with its competitor. While the broader restructuring has been met with initial investor approval, this specific layoff underscores the company's defensive posture as it attempts to regain profitability and market share.

Key Decisions for Investors

• For Novo Nordisk investors, these cost-cutting measures are a necessary defensive action, and they should monitor upcoming quarterly results for evidence of margin improvement and enhanced operational efficiency to justify a long-term position.
• The development reinforces Eli Lilly's current competitive lead, suggesting its leaner operating model provides a near-term advantage; investors may view this as a validation of Lilly's strategy and market position.
• This move signals an escalation in the rivalry within the obesity drug market, and investors should anticipate further strategic adjustments from Novo's new leadership and potential competitive responses from Lilly as the focus shifts from market education to direct market share competition.